Both conditions frequently respond well to IL-1β/IL-1R1-blocking drugs, which argues for excessive/dysregulated IL-1β signaling to play a central role in Still’s disease pathology. Here, IL1R1 is linked to systemic-onset juvenile idiopathic arthritis.